Journal articlePreclinical

Genetic and pharmacological inhibition of two-pore domain potassium channel TREK-1 alters depression-related behaviors and neuronal plasticity in the hippocampus in mice

CNS neuroscience & therapeutics, 2021 Feb. Wu F, Sun H, Gong W and 4 others.

Study type

Journal article

Subjects

Animal / preclinical (no Humans MeSH term)

Journal

CNS neuroscience & therapeutics

Published

2021 Feb

PubMed

PMID 32864894 ↗

DOI

10.1111/cns.13450 ↗

Full text

Free on PubMed Central (PMC7816204) ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

PE-22-28 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AnimalsBridged Bicyclo CompoundsDepressionHippocampusMaleMiceMice, Inbred C57BLNeuronal PlasticityOxazolesPeptidesPotassium Channels, Tandem Pore DomainRNA, Small Interfering

Other papers on PE-22-28

Review · 2019

Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin

Journal article · 2018

The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1

Journal article · 2017

Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page